Wang

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 BIAO WANG, Case No. 21-cv-06028-PCP

Lead Plaintiff,

ORDER ON MOTIONS TO DISMISS

v. AND REQUESTS FOR JUDICIAL

NOTICE

ZYMERGEN INC., et al., Re: Dkt. Nos. 370, 371, 372, and 385-5 Defendants.

12 When materials manufacturing startup Zymergen Inc. went public at $31 per share in 2021, it touted its “biofacturing” process that combines the “efficiency of biological processes” and “technology’s ability to rapidly iterate,” which would allow Zymergen to make products “faster, cheaper and more sustainably than traditional chemistry.” Zymergen’s first product, Hyaline, had launched and the company claimed a “rich pipeline” of other products under development. But a few months later the company revealed that “issues with its commercial product pipeline” would “impact the Company’s delivery timeline and revenue projections” and that the CEO was stepping down. Zymergen’s share price fell 76% the next day, to $8.25. Within a year the company was…